Coherus Oncology (CHRS) Receivables - Net (2013 - 2026)
Coherus Oncology's Receivables - Net came in at $13.88 million for Q2 2026, up 171.7% from $5.11 million a year earlier but down 37.1% from the prior quarter.
Powered by 
Analysis
Coherus Oncology (CHRS) Receivables - Net (2013 - 2026) Analysis & Trends
At the end of FY2025, Coherus Oncology's Receivables - Net was $17.82 million, down 84.0% from FY2024.
- Receivables - Net carries a five-year compound annual growth rate of -35.3% (FY2020 to FY2025).
- Going back by year, Receivables - Net was $111.32 million in FY2024 (-57.3%), $260.52 million in FY2023 (+136.9%), $109.96 million in FY2022 (-10.6%) and $123.02 million in FY2021 (-21.7%).
- The five-year range for quarterly Receivables - Net is $5.11 million (Q2 2025) to $260.52 million (Q4 2023).
- Year-over-year, Receivables - Net increased in 1 of the last eight quarters, with an average decline of 40.4%.
- The fastest year-over-year change in Receivables - Net over five years came in Q2 2026 (growth of 171.7%), and the weakest in Q2 2025 (a decline of 97.1%).
- Business Quant data shows CHRS's Receivables - Net at $22.06 million (Q1 2026), $17.82 million (Q4 2025) and $9.25 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,122.91 Bn | 1,091.50 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 615.09 Bn | 533.62 Bn | 17.26 Bn |
| 3 | AbbVie | 504.75 Bn | 477.86 Bn | 12.70 Bn |
| 4 | Merck | 360.18 Bn | 314.55 Bn | 12.21 Bn |
| 5 | Novartis Ag | 292.05 Bn | 256.04 Bn | 11.24 Bn |
| 6 | Astrazeneca | 256.09 Bn | 229.78 Bn | 12.86 Bn |
| 7 | Amgen | 233.63 Bn | 189.02 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 194.49 Bn | 168.69 Bn | 6.22 Bn |
| 9 | Pfizer | 168.35 Bn | 114.99 Bn | 10.94 Bn |
| 10 | Coherus Oncology | 155.59 Mn | -480.55 Mn | 10.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.88 Mn |
| Mar 31, 2026 | 22.06 Mn |
| Dec 31, 2025 | 17.82 Mn |
| Sep 30, 2025 | 9.25 Mn |
| Jun 30, 2025 | 5.11 Mn |
| Mar 31, 2025 | 60.49 Mn |
| Dec 31, 2024 | 111.32 Mn |
| Sep 30, 2024 | 167.56 Mn |
| Jun 30, 2024 | 175.25 Mn |
| Mar 31, 2024 | 251.95 Mn |
| Dec 31, 2023 | 260.52 Mn |
| Sep 30, 2023 | 216.51 Mn |
| Jun 30, 2023 | 141.31 Mn |
| Mar 31, 2023 | 101.46 Mn |
| Dec 31, 2022 | 109.96 Mn |
| Sep 30, 2022 | 91.19 Mn |
| Jun 30, 2022 | 115.71 Mn |
| Mar 31, 2022 | 117.04 Mn |
| Dec 31, 2021 | 123.02 Mn |
| Sep 30, 2021 | 136.35 Mn |
API Access
Coherus Oncology Receivables - Net API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables-net&ticker=CHRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables-net", "ticker": "CHRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables-net&ticker=CHRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();